13 – 14 May 2020, London, UK.
SMi Group is pleased to announce the third annual Injectable Drug Delivery conference, which will be held in London. Part of Europe’s leading Injectable conference series, Injectable Drug Delivery will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.
With rapid developments in the parenteral space, the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development and innovations in device development, including new therapeutic applications such as the delivery of siRNA. This year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery.
Furthermore, the conference will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.
The two-day agenda also offers peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.
The benefits of attending
This conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following:
- DELVE into the latest work in complex formulation for subcutaneous delivery
- BENCHMARK against leading pharma companies working to enhance device design and development
- UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
- ENGAGE in industry case studies on design controls, human factors and parenteral formulation
- EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops
Who should attend
Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
- Device Engineering
- Human Factors
- Sterile Manufacturing
- Regulatory Affairs
- Alexander Zuern,Device testing manager, Novartis International AG
- Andrew Warrington, Project Leader & Patient Advocate, Novartis
- Benjamin Werner,Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
- Bjorg K Hunter, Regulatory Manager, Devices, GSK
- Blake Green, Senior Manager Regulatory Affairs, Amgen
- Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi
- Christopher Muenzer, Senior Device Technology Manager, Novartis
- Joel Richard,Head of Technical & Pharmaceutical Operations, MedinCell
- Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
- Rebecca Moses, Director, Core Human Factors Inc.
- Rupal Nguyen, Principal Engineer, Allergan
- StefaniaRagone, Pharmaceutical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
- Tina Arien, Principal Scientist, Janssen Pharmaceutica
- Vikas Jaitely, Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck
- Book by 31st January and save £400
- Book by 28th February and save £300
- Book by 29th March and save £200
For further information and to register, please visit:
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.